Quantification of Utilization Management Barriers for Patients Initiating Therapy to Lower Lipid Levels

This cohort study quantifies the rejections that patients with new-to-class claims face when attempting to initiate therapy with PCSK9 inhibitors and explores the association of rejection with subsequent behavior.

Detalles Bibliográficos
Autores principales: O’Neil, Adam, Calderbank, Steve, Brown, James, Vandigo, Joe, Yin, Perry, Bratti, Keith, Howell, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644257/
https://www.ncbi.nlm.nih.gov/pubmed/36346635
http://dx.doi.org/10.1001/jamanetworkopen.2022.40513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644257/
https://www.ncbi.nlm.nih.gov/pubmed/36346635
http://dx.doi.org/10.1001/jamanetworkopen.2022.40513

Ejemplares similares